


#15

RECEIVED


				Complete if Known	
				Application Number	09/574,740
				Filing Date	May 18, 2000
				Confirmation Number	9926
				First Named Inventor	Michael S. South
				Group Art Unit	1614 1624
Examiner Name	T. Truong				
Sheet	1	of	2	Attorney Docket No.	PHA 4160.1(3202/1)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
TNT	64	4,489,096	B1	Terao et al.	12-18-1984
	65	4,851,413	B1	Terao et al.	07-25-1989
	66	4,992,469	B1	Ozawa et al.	02-12-1991
	67	5,008,267		Katakami, et al.	04-16-1991
	68	5,304,658	B1	Terao et al.	04-19-1994
TNT	69	5,741,819	B1	Illig et al.	04-12-1998

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office	Number ⁴	Kind Code ² (if known)			
TNT	70 ✓	DE	198 51 421	A1	Boehringer Ingelheim Pharma KG	05-11-2000	A
TNT	71 ✓	EP	0 354 495	A1	Godecke Aktiengesellschaft	02-14-1990	A
TNT	72 ✓	WO	98/09987	A1 ✗	Biochem Pharma, Inc.	03-12-1998	

Examiner Signature		Date Considered	6/15/04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	09/574,740
Filing Date	May 18, 2000
Confirmation Number	9926
First Named Inventor	Michael S. South
Group Art Unit	1614 1624
Examiner Name	T. Truong
Attorney Docket No.	PHA 4160.1(3202/1)

TECH CENTER 1800/2800

DEC 13 2002

RECEIVED

TNT	73	✓	WO	99/43660	✗	A1	Neurogen Corporation	09-02-1999	
TNT	74	✓	WO	99/48892		A1	Merck & Sharp & Dohme Limited	09-30-1999	
TNT	75	✓	WO	00/69826		A1	Monsanto Company	11-23-2000	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TNT	76 ✓	COBURN, C.A., "Small-molecule direct thrombin inhibitors 1997-2000." Expert Opinions on Therapeutic Patents, 2001, 721-738, Vol. 11, No. 5	
	77 ✓	XP-002172033 - KOHAMA et al., "Preparation of Piperidinylxyacetylaminobenzoylalanine Derivatives and Analogs as Antithrombotics." JP 07,233,148, CA, Vol. 124, ABS # 117979, 1996.	19
	78 ✓	MAJERUS, et al. "Anticoagulant, Thrombolytic, and Antiplatelet Drugs." Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, 1996, pp. 1341-1359, McGraw-Hill, New York.	
	79 ✓	XP-002187583 - MOERNER, Hoppe-Seyler's Z. Physiol. Chem., 69, 1910; 357, 1990.	
TNT	80 ✓	TULINSKY et al., "Novel Asymmetric Synthesis of Atropisomeric 6-Aryl Pyrazinones via an Unusual Chirality Transfer Process." J. Org. Chem., 1999, pp. 93-100, Vol. 64, No. 1.	

Examiner Signature		Date Considered	6/15/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.